Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Conibear

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
The American Journal of Cardiology|May 21, 2023
Pericardial Fluid Analysis in Diagnosis and Prognosis of Patients Who Underwent PericardiocentesisAndrew Sullivan, Adam S C Dennis, Krishnaraj Rathod, et al.
BMJ Open|April 19, 2018
Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancerJohn Conibear, Brendan Chia, Yenting Ngai, et al.
Advances in Radiation Oncology|November 10, 2025
Safety and Efficacy of Stereotactic Magnetic Resonance-Guided Adaptive Radiation Therapy (SMART) for Ultracentral Metastases in Non-Small Cell Lung CancerElena Moreno-Olmedo, Ben George, Kasia Owczarczyk, et al.
BMJ Open|December 10, 2023
Multimodality local consolidative treatment versus conventional care of advanced lung cancer after first-line systemic anti-cancer treatment: study protocol for the RAMON multicentre randomised controlled trial with an internal pilotChloe Beard, Chris A Rogers, Leah Fleming, et al.
BMC Cancer|May 8, 2021
Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United KingdomJason Lester, Carles Escriu, Sarah Khan, et al.
Cancer Medicine|August 12, 2021
Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancerPeter W Szlosarek, Akhila G Wimalasingham, Melissa M Phillips, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 6, 2024
Validated machine learning tools to distinguish immune checkpoint inhibitor, radiotherapy, COVID-19 and other infective pneumonitisSumeet Hindocha, Benjamin Hunter, Kristofer Linton-Reid, et al.
JAMA Oncology|August 30, 2019
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical TrialPeter Schmid, Matthias Zaiss, Catherine Harper-Wynne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2019
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT TrialPeter Schmid, Jacinta Abraham, Stephen Chan, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
The American Journal of Cardiology|May 21, 2023
Pericardial Fluid Analysis in Diagnosis and Prognosis of Patients Who Underwent PericardiocentesisAndrew Sullivan, Adam S C Dennis, Krishnaraj Rathod, et al.
BMJ Open|April 19, 2018
Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancerJohn Conibear, Brendan Chia, Yenting Ngai, et al.
Advances in Radiation Oncology|November 10, 2025
Safety and Efficacy of Stereotactic Magnetic Resonance-Guided Adaptive Radiation Therapy (SMART) for Ultracentral Metastases in Non-Small Cell Lung CancerElena Moreno-Olmedo, Ben George, Kasia Owczarczyk, et al.
BMJ Open|December 10, 2023
Multimodality local consolidative treatment versus conventional care of advanced lung cancer after first-line systemic anti-cancer treatment: study protocol for the RAMON multicentre randomised controlled trial with an internal pilotChloe Beard, Chris A Rogers, Leah Fleming, et al.
BMC Cancer|May 8, 2021
Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United KingdomJason Lester, Carles Escriu, Sarah Khan, et al.
Cancer Medicine|August 12, 2021
Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancerPeter W Szlosarek, Akhila G Wimalasingham, Melissa M Phillips, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 6, 2024
Validated machine learning tools to distinguish immune checkpoint inhibitor, radiotherapy, COVID-19 and other infective pneumonitisSumeet Hindocha, Benjamin Hunter, Kristofer Linton-Reid, et al.
JAMA Oncology|August 30, 2019
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical TrialPeter Schmid, Matthias Zaiss, Catherine Harper-Wynne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2019
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT TrialPeter Schmid, Jacinta Abraham, Stephen Chan, et al.
Pageof 2